Patients with diabetic nephropathy should avoid taking high doses of B vitamins to lower homocysteine levels.

Adding spironolactone to a regimen that includes maximal ACE inhibition improves renoprotection in patients with diabetic nephropathy, data suggest.

Cell adhesion molecules may be potential targets for therapeutic intervention to delay CKD progression.

Renal disease patients who have persistent proteinuria despite treatment with the highest approved dosage of the angiotensin receptor blocker candesartan may benefit from higher dosages, a Canadian study finds.

Diabetic nephropathy and CVD prior to renal transplantation are the most important predictors of post-transplant cardiovascular events, researchers in The Netherlands conclude.

SAN FRANCISCO—British researchers have endorsed U.S. guidelines stating that screening diabetic patients for renal disease should involve estimated glomerular filtration rate (eGFR) in addition to testing for albuminuria.

ALISKIREN, AN oral direct renin inhibitor, may have renoprotective effects that are independent of its BP-lowering effect in patients with type 2 diabetic nephropathy who are receiving the maximal recommended renoprotective treatment and optimal antihypertensive therapy, researchers report.

INTENSIVE GLUCOSE control with gliclazide (modified release) and other agents reduced the risk of nephropathy by one fifth in a large study of patients with type 2 diabetes.

INTENSIVE GLUCOSE control with gliclazide (modified release) and other agents reduced the risk of nephropathy by one fifth in a large study of patients with type 2 diabetes.

ALISKIREN, AN oral direct renin inhibitor, may have renoprotective effects that are independent of its BP-lowering effect in patients with type 2 diabetic nephropathy who are receiving the maximal recommended renoprotective treatment and optimal antihypertensive therapy, researchers report.